Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Keybanc Maintains Overweight on Qualcomm, Raises Price Target to $190

Keybanc analyst John Vinh maintains Qualcomm (NASDAQ:QCOM) with a Overweight and raises the price target from $180 to $190.

byBenzinga Newsdesk

July 29, 2021

1 minute read

Keybanc analyst John Vinh maintains Qualcomm (NASDAQ:QCOM) with a Overweight and raises the price target from $180 to $190.

BTIG Maintains Buy on Inari Medical, Lowers Price Target to $97

By Benzinga Newsdesk

Today, 5:07 AM

BTIG analyst Marie Thibault maintains Inari Medical (NASDAQ:NARI) with a Buy and lowers the price target from $100 to $97.

NARI

News

Mandalay Bay Announces $100M Remodel Of 2.1 Million-Square-Foot Convention Center

By Benzinga Newsdesk

Today, 5:07 AM

Enhancements Feature Upgraded Technology and Bright, Refreshing Spaces Designed for Next Generation of Meetings and Events LAS VEGAS, Oct. 12, 2022 /PRNewswire/ -- Recognized as one of the country's

MGM

Nio Surges As Singapore Listing Announced For May 20: What Investors Should Know

By Shanthi Rexaline

Today, 5:07 AM

Nio, Inc. (NASDAQ: NIO) confirmed Wednesday its secondary listing in Singapore is expected to happen later this month.

NIO

Eiger BioPharma Offers Expectations For 2022 Catalysts, Milestones

By Benzinga Newsdesk

Today, 5:07 AM

- Phase 3 HDV D-LIVR (Lonafarnib) Study Topline Data Planned by End of 2022 - Phase 3 HDV LIMT-2 (Peginterferon Lambda) Study Enrolling and Dosing - Phase 3 COVID-19 TOGETHER (Peginterferon Lambda) Study Topline Data

EIGR

Keybanc Maintains Overweight on Qualcomm, Raises Price Target to $190

Related Posts

BTIG Maintains Buy on Inari Medical, Lowers Price Target to $97

Mandalay Bay Announces $100M Remodel Of 2.1 Million-Square-Foot Convention Center

Nio Surges As Singapore Listing Announced For May 20: What Investors Should Know

Eiger BioPharma Offers Expectations For 2022 Catalysts, Milestones